Generics BulletinFresenius Kabi’s Tyenne (tocilizumab) biosimilar to Actemra/RoActemra is “progressing rapidly, in line with expectations, showing dynamic month-by-month growth,” following its launch in more than 20 c
Generics BulletinFresenius Kabi will look to launch its denosumab biosimilars to Prolia and Xgeva in the US in mid-2025, after the German firm received US Food and Drug Administration approval for the biosimilars – th
Generics BulletinPierluigi Antonelli was less than three months into his role as a member of the Management Board of Fresenius, responsible for the group’s operating company Fresenius Kabi, when he recognised an eye
Generics Bulletin“We are a simpler, stronger, and more focused company. 2024 looks to be a great year with excellent financial progression,” Fresenius ’ CEO Michael Sen did not hide his enthusiasm about the future du